secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001493152-24-011627
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix reports FY2023 net loss narrowed; cash runway extended to Q1 2026 on Cipla amendment
--------------------------------------------------------------------------------

- Cash and equivalents $19.2M at Dec 31, 2023; projected runway into Q1 2026.
- Net loss $14.1M ($3.87/share) for FY2023, improved from $18.8M ($5.46/share) in FY2022.
- Revenue $7.3M, up $1.2M YoY due to higher PUR1900 activity under Cipla agreement.
- Cipla amendment: wind-down of PUR1900 Phase 2b; Pulmatrix gets 2% royalty on net sales, no further development cost.
- R&D spend fell $2.7M to $15.5M; G&A fell $0.3M to $6.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315224011627/0001493152-24-011627-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315224011627/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-011627

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer